Form 4: Outlook Therapeutics Director Receives Stock Option Grants

Randy H. Thurman, a director at Outlook Therapeutics, received two stock option grants on October 1, 2024, which will fully vest on October 1, 2025, subject to continuous service.

Summary

• On October 1, 2024, Randy H. Thurman, a director of Outlook Therapeutics, received two stock option grants.
• The first grant is for 56,636 shares with an exercise price of $5.22, vesting on October 1, 2025.
• The second grant is for 89,549 shares with an exercise price of $5.22, also vesting on October 1, 2025.
• Both grants are subject to acceleration upon a Change in Control, as defined in the company's 2024 Equity Incentive Plan, provided the director maintains continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it incentivizes the director.

Positives

• The stock option grants incentivize the director to remain with the company and contribute to its success.
• The vesting schedule aligns the director's interests with those of the shareholders.

Risks

• The value of the stock options is dependent on the future performance of Outlook Therapeutics' stock price.
• The director must maintain continuous service to vest the options, creating a potential risk of losing the incentive if service is terminated.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like Ocular Therapeutix and Aldeyra Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grants aim to align the director's interests with those of the shareholders, potentially leading to increased shareholder value.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates